Prognostic value of bcl-2 expression in invasive breast cancer.
Prognostic value of bcl-2 expression in invasive breast cancer.
复制标题
DOI：
10.1038/bjc.1995.338
复制
发表时间：
1995-08
影响因子：
8.8
通讯作者：
Van Marck, E
中科院分区：
文献类型：
--
作者：
Hellemans, P;van Dam, P A;Weyler, J;van Oosterom, A T;Buytaert, P;Van Marck, E
应用免疫组织化学方法检测251例浸润性导管癌(中位随访时间91个月，范围24~186个月)中bcl2原癌基因的表达，并与临床病理资料和预后因素进行相关分析。63个肿瘤(25%)bcl2阴性，188个(75%)bcl2阳性。未观察到bcl2表达与肿瘤分级、pTNM分期或绝经状态有关。Bcl2免疫反应与雌激素受体状态(P<；0.001)和孕激素受体状态(P<；0.001)呈显著正相关。在腋窝淋巴结阴性的乳腺癌患者中，bcl2的表达对无瘤生存期和总生存期没有预后价值。然而，在腋窝淋巴结阳性的乳腺癌患者中，多因素分析显示bcl2表达缺失与无病生存期缩短(P=0.003)和总生存期缩短(P<；0.001)独立相关。我们的结果提示bcl2的表达作为乳腺癌辅助治疗反应的调节器具有潜在的重要作用。
Expression of the bcl-2 proto-oncogene was studied immunohistochemically in 251 invasive ductal breast carcinomas (median follow-up time 91 months, range 24-186 months) and the results were correlated with clinicopathological data and prognostic variables. Sixty-three (25%) tumours were scored bcl-2 negative and 188 (75%) tumours were bcl-2 positive. No relationship could be observed between bcl-2 status and tumour grade, pTNM staging or menopausal status. A strong positive relationship was demonstrated between bcl-2 immunoreactivity and oestrogen receptor status (P < 0.001) and progesterone receptor status (P < 0.001). No prognostic value was demonstrated for bcl-2 expression on disease-free survival and overall survival in axillary node-negative breast cancer patients. However, in axillary node-positive breast cancer patients multivariate analysis demonstrated absence of bcl-2 expression to be independently related to shortened disease-free survival (P = 0.003) and shortened overall survival (P < 0.001). Our results suggest a potential important role for bcl-2 expression as a modulator of response to adjuvant therapy in breast cancer.